Assessing the benefit–risk profile of newer glucose‐lowering drugs: A systematic review and network meta‐analysis of randomized outcome trials
Authors' conclusion
Given the distinct benefit-risk profiles, the selection of glucose-lowering drugs should be individualized based on patient characteristics and risk factors.
Study context
- Population
- Adults with T2D, HF or CKD in randomised cardiovascular and kidney outcome trials (PubMed, EMBASE, CENTRAL to November 2023)
- Participants
- 198,177 adults26 trials
- Comparison
- GLP-1 RA, DPP-4i or SGLT2i vs placebo
- Outcome
- Benefit outcomes vs placebo (21 outcomes assessed)
Methodological detailspopulation-averaged odds ratios (ORs)
- Population-averaged ORs
Pooled result
As reported in the abstract
Odds ratio (95% CI)
GLP-1RAvs PlaceboMACE; GLP-1RA most effective
0.85(0.79–0.92)
GLP-1RAvs PlaceboStroke; GLP-1RA most effective
0.84(0.77–0.91)
SGLT2ivs PlaceboHHF; SGLT2i greatest benefit
0.68(0.64–0.73)
SGLT2ivs PlaceboComposite renal outcomes; SGLT2i greatest benefit
0.67(0.58–0.77)
DPP4ivs PlaceboParkinson's disease
0.54(0.32–0.92)
- Between DPP4i and Placebo · Amputation
- OR 0.70 (95% CI 0.86–0.93)
Safety
| Outcome | OR (CI) | |
|---|---|---|
| Harms vs placeboGLP-1RAvs PlaceboThyroid cancer | 1.58 (1.36–2.50) | |
| Harms vs placeboSGLT2ivs PlaceboGenital infections | 3.11 (2.15–4.50) | |
| Harms vs placeboDPP4ivs PlaceboNeuropathy | 1.10 (1.02–1.18) | |
| Harms vs placeboDPP4ivs PlaceboPancreatitis | 1.63 (1.40–1.91) | |
| 0.20.5125Odds ratio (log scale) |
Original publication
Assessing the benefit–risk profile of newer glucose‐lowering drugs: A systematic review and network meta‐analysis of randomized outcome trials. Diabetes Obes Metab. Published 26 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →